𝔖 Bobbio Scriptorium
✦   LIBER   ✦

OP-09 Pharmacokinetic characteristics of the new treatment combination of sorafenib and resminostat, a novel histone deacetylase (HDAC) inhibitor, in patients with advanced hepatocellular carcinoma (HCC): The SHELTER study

✍ Scribed by Hauns, B.; Mais, A.; Doblhofer, R.; Henning, S.W.; Hentsch, B.; Bitzer, M.


Book ID
122043786
Publisher
Elsevier Science
Year
2013
Tongue
English
Weight
58 KB
Volume
45
Category
Article
ISSN
1590-8658

No coin nor oath required. For personal study only.